{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:20:04Z","timestamp":1770834004785,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"7644","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2017,3,9]]},"DOI":"10.1038\/543174a","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T10:16:06Z","timestamp":1488536166000},"page":"174-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Show drugs work before selling them"],"prefix":"10.1038","volume":"543","author":[{"given":"Douglas","family":"Sipp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E. J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"BF543174a_CR1","first-page":"25","volume-title":"A Quick Guide to Clinical Trials","author":"SW Junod","year":"2008","unstructured":"Junod, S. W. In A Quick Guide to Clinical Trials (eds Davies, M. & Kerimani, F.) 25\u201355 (Bioplan, 2008); available at http:\/\/go.nature.com\/2kjhny4"},{"key":"BF543174a_CR2","first-page":"CD008185","volume":"2","author":"EMK Da Silva","year":"2016","unstructured":"Da Silva, E. M. K., Strufaldi, M. W. L., Andriolo, R. B. & Silva, L. A. Cochrane Database Syst. Rev. 2, CD008185 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BF543174a_CR3","unstructured":"US Food and Drug Administration. 22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results (FDA, 2017); available at http:\/\/go.nature.com\/2mayug4"},{"key":"BF543174a_CR4","unstructured":"Henderson, D. R. 'Markets Can Determine Drug Efficacy' Forbes (8 July 2009); available at http:\/\/go.nature.com\/2kbkzps"},{"key":"BF543174a_CR5","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMms1604593","volume":"374","author":"LE Bothwell","year":"2016","unstructured":"Bothwell, L. E., Greene, J. A., Podolsky, S. H. & Jones, D. S. N. Engl. J. Med. 374, 2175\u20132181 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BF543174a_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamainternmed.2013.11813","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore, T. J. & Furberg, C. D. JAMA Intern. Med. 174, 90\u201395 (2014).","journal-title":"JAMA Intern. Med."},{"key":"BF543174a_CR7","doi-asserted-by":"publisher","first-page":"D1080","DOI":"10.1093\/nar\/gkv1192","volume":"44","author":"VB Siramshetty","year":"2016","unstructured":"Siramshetty, V. B. et al. Nucleic Acids Res. 44, D1080\u2013D1086 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/543174a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/543174a","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/543174a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T13:47:46Z","timestamp":1743688066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/543174a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":7,"journal-issue":{"issue":"7644","published-print":{"date-parts":[[2017,3,9]]}},"alternative-id":["BF543174a"],"URL":"https:\/\/doi.org\/10.1038\/543174a","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]},"assertion":[{"value":"9 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E.J.R. is Director of Pathology and a shareholder at the IVF company Genea. He has a management\/advisory relationship with the Cure The Future Foundation (honorary Board Member), FSHD Global Research Foundation (honorary Scientific Patron) and New Directions in Leukaemia Research (honorary Scientific Committee member). He is President-Elect 2016\u201318 of the International Society for Cellular Therapy, which may have links to companies and affiliations with interests in medical technology development. He chairs the RPA Hospital Institutional Biosafety Committee and has chaired the federal Gene Technology Technical Advisory Committee of the Office of the Gene Technology Regulator, Australian Government, for the past ten years. His Department of Cell & Molecular Therapies is involved in clinical development of gene-modified cells, often in collaboration with companies such as Miltenyi, Terumo, Sillajen, Athersys, Cynata and Novartis. Some or all of these are covered by confidential disclosure agreements. He has had paid consulting relationships and\/or travel support, as follows: (i) Honoraria for speaking and\/or as part of clinical trials by GSK, Spark, Novartis, bluebird bio; (ii) Rarecyte (past scientific consultant, stocks in lieu); (iii) Imago (scientific consultant). His employer, Sydney Local Health District, NSW Government, assisted with travel as part of his salary package for training education and service leave.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}